Literature DB >> 4038757

[Thrombotic thrombocytopenic purpura].

C Aul, R E Scharf, T Königshausen, W Schneider.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is an uncommon disorder which usually occurs in young adults. It is characterized by a pentad of clinical findings: fever, neurological abnormalities, renal dysfunction, microangiopathic hemolytic anemia and thrombocytopenia. The histological hallmark is the presence of platelet thrombi occluding the microcirculation of multiple organs. The etiology and pathogenesis of disseminated platelet aggregation are uncertain and obviously not uniform in individual patients. Experimental findings suggest that microthrombi may result from intravascular platelet activation or form secondarily at sites of vessel wall damage. The differential diagnosis of TTP includes the hemolytic uremic syndrome in which the microangiopathic changes are exclusively found in the kidneys. When untreated, TTP invariably runs a progressive and fatal course. In recent years, prognosis has been improved by new forms of therapy such as plasmapheresis or infusions of fresh frozen plasma which may lead to recovery in about 80% of patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038757     DOI: 10.1007/bf01734250

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  58 in total

1.  Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.

Authors:  M A RUBINSTEIN; B M KAGAN; M H MACGILLVIRAY; R MERLISS; H SACKS
Journal:  Ann Intern Med       Date:  1959-12       Impact factor: 25.391

2.  Morphology of thrombotic thrombocytopenic purpura with demonstration of aneurysms.

Authors:  J L ORBISON
Journal:  Am J Pathol       Date:  1952 Jan-Feb       Impact factor: 4.307

3.  Thrombotic thrombocytopenic purpura; treatment with antiplatelet agents.

Authors:  G B Faguet; M B King
Journal:  Am J Med Sci       Date:  1974-08       Impact factor: 2.378

4.  Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma.

Authors:  E C Lian; D R Harkness; J J Byrnes; H Wallach; R Nunez
Journal:  Blood       Date:  1979-02       Impact factor: 22.113

5.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

6.  Plasma exchange transfusion.

Authors:  E G Taft; S T Baldwin
Journal:  Semin Thromb Hemost       Date:  1981       Impact factor: 4.180

7.  Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production.

Authors:  K A Jørgensen; E Stoffersen
Journal:  Pharmacol Res Commun       Date:  1981-06

Review 8.  Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.

Authors:  M C Brain; P B Neame
Journal:  Semin Thromb Hemost       Date:  1982-07       Impact factor: 4.180

9.  Elevated platelet-associated IgG in thrombotic thrombocytopenic purpura.

Authors:  J Morrison; R McMillan
Journal:  JAMA       Date:  1977-10-31       Impact factor: 56.272

10.  CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis.

Authors:  J F Bale; C Brasher; R L Siegler
Journal:  Am J Dis Child       Date:  1980-09
View more
  2 in total

1.  Platelet factor 4 and the response to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

Authors:  G Wiedemann; I Kantner; M Schenke; E Schulz; T Wagner
Journal:  Klin Wochenschr       Date:  1989-05-15

2.  Thrombotic thrombocytopenic purpura without anemia.

Authors:  J Barnert; W Behr; G Schlimok
Journal:  Klin Wochenschr       Date:  1986-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.